Septerna (NASDAQ:SEPN) Price Target Raised to $50.00 at Wells Fargo & Company

Septerna (NASDAQ:SEPN) had its price target increased by equities research analysts at Wells Fargo & Company from $48.00 to $50.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 4.69% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Truist Financial increased their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Guggenheim lifted their price target on shares of Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. HC Wainwright increased their price objective on Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Stifel Nicolaus set a $49.00 target price on shares of Septerna in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $49.22.

Septerna Stock Performance

Shares of NASDAQ:SEPN opened at $47.76 on Wednesday. Septerna has a 52 week low of $10.62 and a 52 week high of $48.00. The firm has a market cap of $2.15 billion, a PE ratio of -88.44 and a beta of 2.29. The firm’s fifty day moving average is $34.94 and its 200-day moving average is $29.25.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.14. The firm had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative return on equity of 9.59% and a negative net margin of 24.51%. Sell-side analysts forecast that Septerna will post -1.59 EPS for the current year.

Insider Buying and Selling at Septerna

In other news, SVP Daniel D. Long sold 15,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,423,590.12. This represents a 13.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. The trade was a 93.70% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 47,828 shares of company stock worth $1,584,314. 5.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Septerna

A number of institutional investors have recently added to or reduced their stakes in SEPN. Deutsche Bank AG lifted its position in Septerna by 5.3% during the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock valued at $415,000 after acquiring an additional 744 shares during the period. Global Retirement Partners LLC purchased a new stake in Septerna in the fourth quarter worth about $35,000. JPMorgan Chase & Co. increased its stake in shares of Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares in the last quarter. PharVision Advisers LLC increased its stake in shares of Septerna by 17.5% during the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares in the last quarter. Finally, Nuveen LLC lifted its holdings in shares of Septerna by 7.7% during the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock valued at $719,000 after purchasing an additional 1,837 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.